SCHEMBL10314724

SCHEMBL10314724

CN(C)CI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15505384 0.74
Propylene Glycol SCHEMBL21081777 0.73 TDP1 (0.59)
SCHEMBL12956614 0.70
SCHEMBL14066482 0.70
SCHEMBL14668872 0.70
SCHEMBL20160000 0.67
SCHEMBL308533 0.67
Trimethylammonium SCHEMBL3145918 0.67
Trimethylammonium SCHEMBL934820 0.67
SCHEMBL98451 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4299064-A2 TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY THE CLEVELAND CLINIC FOUNDATION (US) 2024-01-03 EP claimed
EP-3641748-B1 TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY CLEVELAND CLINIC FOUND (US) 2023-11-29 EP claimed
CN-113402535-A 4-cation disubstituted BODIPY compound and preparation method and application thereof 复旦大学 2021-09-17 CN claimed
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels THE CLEVELAND CLINIC FOUNDATION (US) 2026-03-17 US disclosed
US-20240165131-A1 TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS THE CLEVELAND CLINIC FOUNDATION 2024-05-23 US disclosed
US-20240139120-A1 TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY THE CLEVELAND CLINIC FOUNDATION 2024-05-02 US disclosed
US-11911399-B2 Treating and preventing disease with TMA and TMAO lowering agents THE CLEVELAND CLINIC FOUNDATION (US) 2024-02-27 US disclosed
EP-4299064-A2 TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY THE CLEVELAND CLINIC FOUNDATION (US) 2024-01-03 EP disclosed
EP-3641748-B1 TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY CLEVELAND CLINIC FOUND (US) 2023-11-29 EP disclosed
US-11771659-B2 Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway THE CLEVELAND CLINIC FOUNDATION (US) 2023-10-03 US disclosed
US-9617291-B2 Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2017-04-11 US disclosed
US-8513443-B2 Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-3,4-difluoro-2(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide ARDEA BIOSCIENCES, INC. (US) 2013-08-20 US disclosed
EP-2129659-B1 ALPHA-HYDROXYKETONES BASF SE (DE) 2013-05-29 EP disclosed
WO-2012103059-A2 BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-08-02 WO disclosed
US-20120178946-A1 PREPARATION OF (R)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND (S)- N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE ARDEA BIOSCIENCES ,INC. (US) 2012-07-12 US disclosed
US-20110220311-A1 REDUCTION OF THE ADSORPTION OF QUATERNARY AMMONIUM SALTS ONTO CELLULOSIC FIBERS WEYERHAEUSER NR COMPANY (US) 2011-09-15 US disclosed
CN-101392060-B Quaternized polybenzimidazoles and preparation method thereof UNIV DONGHUA 2011-01-12 CN disclosed
EP-2161320-A2 Fluorene derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-03-10 EP disclosed
WO-2009076404-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR EPIX DELAWARE, INC. (US) 2009-06-18 WO disclosed
CN-101392060-A Quaternized polybenzimidazoles and preparation method thereof UNIV DONGHUA (CN) 2009-03-25 CN disclosed